Seven Fleet Capital Management LP boosted its position in Celcuity, Inc. (NASDAQ:CELC – Free Report) by 170.9% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 16,252 shares of the company’s stock after acquiring an additional 10,252 shares during the quarter. Seven Fleet Capital Management LP’s holdings in Celcuity were worth $1,700,000 as of its most recent SEC filing.
Other institutional investors have also added to or reduced their stakes in the company. Parallel Advisors LLC bought a new position in Celcuity in the first quarter worth approximately $38,000. EverSource Wealth Advisors LLC increased its holdings in shares of Celcuity by 1,329.2% during the fourth quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock valued at $34,000 after acquiring an additional 319 shares in the last quarter. Meeder Asset Management Inc. acquired a new position in shares of Celcuity during the fourth quarter worth approximately $42,000. PNC Financial Services Group Inc. raised its position in shares of Celcuity by 20.1% during the first quarter. PNC Financial Services Group Inc. now owns 514 shares of the company’s stock worth $59,000 after purchasing an additional 86 shares during the period. Finally, KBC Group NV bought a new position in shares of Celcuity in the 1st quarter worth $64,000. 63.33% of the stock is owned by institutional investors and hedge funds.
Celcuity Stock Up 3.0%
CELC stock opened at $95.08 on Thursday. The firm has a market capitalization of $4.65 billion, a PE ratio of -22.11 and a beta of 0.20. The company has a quick ratio of 8.93, a current ratio of 8.93 and a debt-to-equity ratio of 6.04. Celcuity, Inc. has a twelve month low of $44.42 and a twelve month high of $151.02. The stock’s 50 day moving average is $94.52 and its 200-day moving average is $107.38.
Analysts Set New Price Targets
Several research firms recently issued reports on CELC. Stifel Nicolaus reduced their price target on shares of Celcuity from $175.00 to $150.00 and set a “buy” rating for the company in a research report on Friday, August 14th. Macquarie Infrastructure set a $160.00 price objective on shares of Celcuity in a report on Thursday, May 28th. Citigroup reaffirmed a “market outperform” rating on shares of Celcuity in a research note on Monday, August 17th. Citizens Jmp reiterated a “market outperform” rating and set a $177.00 price objective on shares of Celcuity in a report on Monday, August 17th. Finally, HC Wainwright reissued a “buy” rating and set a $155.00 target price on shares of Celcuity in a research report on Friday, August 14th. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $154.55.
Get Our Latest Analysis on CELC
Celcuity Company Profile
Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.
Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.
Featured Articles
- Five stocks we like better than Celcuity
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Want to see what other hedge funds are holding CELC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celcuity, Inc. (NASDAQ:CELC – Free Report).
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.
